A Phase 1 interventional study of Nemtabrutinib in Severe Renal Impairment and Healthy, sponsored by Merck Sharp & Dohme LLC. Recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-23.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Among 22 studies in Renal Insufficiency by Merck Sharp & Dohme LLC — 2 open to participants now, 2 under way, none of them phase 3. Renal Insufficiency · Merck Sharp & Dohme LLC.
Among the 22 studies in Renal Insufficiency by Merck Sharp & Dohme LLC, this one is the 14th largest by planned enrollment, is one of 3 that started in 2026, is one of 22 in phase 1, and was the 21st registered.
1,409 studies on the registry are indexed under Renal Insufficiency; 143 are open to participants now.
This study's planned enrollment of 20 is below the median of 40 across 1,058 interventional studies indexed under Renal Insufficiency.
Browse Renal Insufficiency studies →2 of the 22 studies in Renal Insufficiency by Merck Sharp & Dohme LLC are open now, in 1 country. Each count lists the studies.
Of the 90 Renal Insufficiency studies recruiting now, 47 (52%) set no upper age limit and 18 (20%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →22 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 3 started in 2026.
Median enrollment 24 across the 22 interventional studies. Of the 19 that completed or were terminated, 15 (79%) have results posted.
Merck Sharp & Dohme LLC is the lead sponsor of 2,166 studies on the registry; 132 are open to participants now.
Of its 501 completed or terminated interventional studies of FDA-regulated products, 370 (74%) have results posted.
2 of the studies in Renal Insufficiency by Merck Sharp & Dohme LLC that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07734610Merck Sharp & Dohme LLCA Clinical Trial of Nemtabrutinib in Participants With Severe Kidney Disease (MK-1026-027) | 2027-02-01 |
| NCT07922174Merck Sharp & Dohme LLCA Clinical Trial of MK-6916 in Participants With Moderate and Severe Kidney Disease Compared to Healthy Controls (MK-6916-013) | 2027-08-06 |
Among the 22 studies in Renal Insufficiency by Merck Sharp & Dohme LLC, from their registry updates:
The purpose of this study is to learn what happens to nemtabrutinib in a person's body when given to participants with severe kidney disease and to healthy participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The main inclusion criteria include but are not limited to the following:
All participants:
Participants with Severe Renal impairment (RI):
Healthy volunteers:
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
Renal Impairment Participants:
Healthy Matched Control Participants:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants will receive a single oral dose of nemtabrutinib on Day 1.
Drug: Nemtabrutinib
Oral administration
Also known as: MK-1026
Area Under the Concentration Time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Nemtabrutinib in Plasma
Blood samples will be collected to determine the AUC0-inf of Nemtabrutinib in plasma.
Time frame: At designated timepoints up to approximately 336 hours postdose
Area Under the Concentration Versus Time Curve from 0 to the Time of the Last Quantifiable Sample (AUC0-last) of Nemtabrutinib
Blood samples will be collected to determine the AUC0-last of Nemtabrutinib in plasma.
Time frame: At designated timepoints up to approximately 336 hours postdose
Area Under the Concentration Versus Time Curve from 0 to 24 Hours Postdose (AUC0-24) of Nemtabrutinib
Blood samples will be collected to determine the AUC0-24 of Nemtabrutinib.
Time frame: Up to approximately 24 hours postdose
Maximum Plasma Concentration (Cmax) of Nemtabrutinib in Plasma
Blood samples will be collected to determine the (Cmax) of Nemtabrutinib.
Time frame: At designated timepoints up to approximately 336 hours postdose
Concentration at 24 Hours Postdose (C24) of Nemtabrutinib in Plasma
Blood samples will be collected to determine the C24 of Nemtabrutinib.
Time frame: Up to approximately 24 hours postdose
Time of the Maximum Observed Concentration (Tmax) of Nemtabrutinib in Plasma
Blood samples will be collected to determine the (Tmax) of Nemtabrutinib.
Time frame: At designated timepoints up to approximately 336 hours postdose
Time of the Maximum Observed Concentration (t1/2) of Nemtabrutinib in Plasma
Blood samples will be collected to determine the (t1/2) of Nemtabrutinib.
Time frame: At designated timepoints up to approximately 336 hours postdose
Apparent Total Plasma Clearance (CL/F) of Nemtabrutinib
Blood samples will be collected to determine the CL/F of Nemtabrutinib.
Time frame: At designated timepoints up to approximately 336 hours postdose
Apparent Volume of Distribution During the Terminal Elimination Phase (Vz/F) of Nemtabrutinib in Plasma
Blood samples will be collected to determine the Vz/F of Nemtabrutinib.
Time frame: At designated timepoints up to approximately 336 hours postdose
Number of Participants Who Experience an Adverse Event (AE)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported.
Time frame: Up to approximately 15 days
Number of Participants Who Discontinue From the Study Due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue from the study due to an AE will be reported.
Time frame: Up to approximately 15 days
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Started Sep 2026 (actual). Primary completion is estimated for Feb 2027, 4 months after the start.
Of 212 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 4 months is below that.
Counting every sponsor, half of 230 studies reached it within 8 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ARQ531